Eton Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M | $21.8M |
| Gross profit | $42.7M | $23.4M | $21.1M | $14.3M | $19.0M |
| Operating income | -$844,000 | -$2.6M | -$1.2M | -$8.3M | -$1.5M |
| Operating expenses | $43.6M | $26.0M | $22.3M | $22.6M | $20.5M |
| Cost of revenue | $37.2M | $15.6M | $10.6M | $6.9M | $2.8M |
| Cash from operations | $10.5M | $969,000 | $6.8M | $4.8M | -$4.7M |
| Capital expenditure | $333,000 | $26,000 | $0 | $38,000 | $9,000 |
| Free cash flow | $10.2M | $943,000 | $6.8M | $4.8M | -$4.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $92.1M | $76.1M | $31.7M | $25.0M | $27.5M |
| Total liabilities | $66.0M | $51.7M | $16.3M | $12.0M | $9.8M |
| Total debt | — | — | $5.5M | $6.6M | $7.0M |
Shares outstanding 27.4M · Free float 95.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.